ClinicalTrials.gg
RecruitingNCT07301918Updated Jun 4, 2026

Leaf Expander Versus Hyrax Expander in Mixed Dentition Patients With Posterior Crossbite.

An interventional study of The Leaf expander and Hyrax expander in Posterior Crossbite and Maxilla; Hypoplasia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Cairo University · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

Design: Two-arm parallel randomized clinical trial in mixed dentition (6-12 years).

Arms: (1) 9 mm, 900 g leaf expander; (2) 9 mm Hyrax expander. Follow-up: From appliance insertion → completion of intended expansion → 6-month retention.

Primary outcome: Pain perception during the first 7 days post-insertion (daily patient-reported scale).

Secondary outcomes: Skeletal and dental changes on CBCT.

Read the detailed description

Participants receive a banded maxillary expansion appliance cemented to maxillary first permanent molars, assigned to:

Leaf expander arm: Nickel-titanium leaf-spring expander, 9 mm screw, delivering force of \~900 g.

Hyrax expander arm: Conventional tooth-borne jackscrew expander, 9 mm screw. Standard activation: two turns per week.

Retention: Both appliances kept passively in situ for 6 months of retention following achievement of planned expansion.

02

Conditions studied

  • Posterior Crossbite
  • Maxilla; Hypoplasia

Browse trials for

Keywords

  • expander
  • maxillary transverse deficiency
  • posterior crossbite
  • mixed dentition
03

In context

Retrognathia

62 studies on the registry are indexed under Retrognathia; 15 are open to participants now.

This study's planned enrollment of 30 is below the median of 34 across 52 interventional studies indexed under Retrognathia.

Browse Retrognathia studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients
  • Mixed dentition stage
  • Unilateral or bilateral posterior crossbite.
  • Patients in prepubertal stage with cervical vertebral maturation stage 1-3.
  • Fully erupted maxillary and mandibular permanent first molars.
  • Skeletal class I or II.

Exclusion criteria

Exclusion Criteria:

  • Previous orthodontic treatment.
  • Missing teeth.
  • Inadequate oral hygiene.
  • Patients with bad oral habits.
  • Patients with medical conditions.
  • Patients with cleft lip and palate.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Banded Leaf expander supported on the maxillary first permanent molars

    9mm leaf expander delievering 900 gm force will be supported on the upper first permanent molars with the appliance arm extending to the canines

    Device: The Leaf expander

  • Active comparator
    Banded Hyrax expander supported on the maxillary first permanent molars

    9mm Hyrax expander will be supported on the upper first permanent molars with the appliance arm extending to the canines

    Device: Hyrax expander

Interventions

  • DeviceThe Leaf expander

    The Leaf expander incorporates Nickel Titanium springs that will not require the patients' home activation

  • DeviceHyrax expander

    Hyrax expander incorporates a screw that requires the patients' home activation

06

What researchers measure

Primary outcomes

  1. Pain perception

    Pain perception during the first week after insertion using Wong-Becker faces scale with minimum value of zero and maximum value of ten, ten score represents the worst pain percieved.

    Time frame: first week after appliance insertion

Secondary outcomes

  1. skeletal expansion

    skeletal expansion using Cone Beam Computed Tomography skeletal expansion: linear distances of the midpalatal suture opening measured in mm between the pre- and post-axial cuts of the CBCT

    Time frame: 6 months post expansion

  2. dental tipping

    Angular measurement of upper first molars angulation measured in degrees between pre- and post-coronal cuts of the CBCT

    Time frame: 6 months post-expansion

  3. digital models parameters

    Intermolar width, intercanine width

    Time frame: six months post-expansion

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07301918
Lead sponsor
Cairo University
Responsible party
Noura Mohamed Hamza Hassan Saleh (Principal investigator, Cairo University) — Principal investigator
First posted
Dec 24, 2025
Start date
Oct 1, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jun 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion